Background: Anesthesia for craniotomies should blunt responses to noxious stimuli, whereas subsequently leaving patients sufficiently alert for early neurological evaluation. The aim was to compare postoperative blood pressure control, pain, and opioid requirement after anesthesia with dexmedetomidine versus remifentanil. We therefore tested 2 primary hypotheses: (1) intraoperative administration of dexmedetomidine provides better control of postoperative blood pressure than remifentanil; and (2) patients given dexmedetomidine have less postoperative pain and use less opioid.
A nesthesia for a craniotomy is challenging because brief periods of intense stimulation 1,2 are interposed with long periods of little stimulation. The postoperative course of patients undergoing intracranial procedures with general anesthesia is often complicated by hypertension. 3 Intraoperative hypertensive episodes consequent to noxious stimuli and early postoperative hypertensive episodes consequent to impairment of autoregulation in the tumor resection bed 4 may be associated with postcraniotomy intracranial hemorrhage and vasogenic edema. 5 Patients with postoperative intracranial hemorrhage were shown to have 3.4 times the odds of being hypertensive during hemorrhage than matched controls. 6 Short-acting potent analgesics such as remifentanil are frequently used in this type of surgery. Remifentanil, which is largely a m1 agonist, is rapidly metabolized by plasma esterases; it thus has a context-sensitive half-life of only 3 minutes 7 and does not accumulate. 8 The drug can be rapidly titrated to changing intraoperative conditions, typically providing good protection from intraoperative hypertension. 9 A consequence of remifentanil's short half-life is that it provides little postoperative analgesia. Furthermore, remifentanil promotes hyperalgesia by activating spinal delta-opioid receptors which in turn activate N-methyl-D-aspartate receptors, 10 causing hyperalgesia, 11 which increases postoperative analgesic requirements 12 and promotes hypertension. 13 A promising alternative to remifentanil is dexmedetomidine, a potentially neuroprotective 14 alpha-2 adrenoceptor agonist. The drug is sympatholytic and may thus attenuate hypertension. It is also antinociceptive and opioid sparing, [15] [16] [17] [18] and reduces intraoperative anesthetic requirements. 19 However, dexmedetomidine has a much longer context-sensitive half-life than remifentanil (about 4 min after an infusion of 10 and 250 min after an infusion of 8 h), 20 which may slow recovery and diminish postoperative patient responses.
The postoperative consequences of intraoperative remifentanil and dexmedetomidine use in neurosurgical patients remain unclear. We therefore tested the 2 primary hypotheses that (1) intraoperative administration of dexmedetomidine provides better control of postoperative blood pressure than remifentanil, and (2) patients given dexmedetomidine have less postoperative pain and require less opioid. Secondarily, we assessed the differences in postoperative heart rate, recovery speed, immediate postoperative memory and concentration, and nursing resource usage.
MATERIALS AND METHODS
This trial was registered at ClinicalTrials.gov (NCT01269918). With Institutional Review Board approval, we obtained written consent from adults scheduled for elective surgical excision of a brain tumor (open craniotomy or transsphenoidal approach) under balanced general anesthesia with endotracheal intubation.
We excluded patients who had a body mass index exceeding 45 kg/m 2 , uncontrolled hypertension, cardiac conduction defects, chronic pain requiring opioid analgesia, or reported allergy to either study drug, as well as patients having awake craniotomies or craniotomies requiring intraoperative magnetic resonance scanning (because the length of surgery was much longer).
Protocol
Patients were randomly assigned to either a remifentanil or dexmedetomidine infusion during anesthetic maintenance. Randomization was based on computergenerated codes with permuted blocks and no stratification. Allocation was concealed until just before surgery when investigators opened sequentially numbered opaque envelopes.
Remifentanil was given by infusion at a rate of 0.08 to 0.15 mg/kg/min and was discontinued at the end of surgery when the patient's head was removed from the pins of the head holder. Patients assigned to dexmedetomidine were given a loading dose of 0.5 to 1 mg/kg ideal body weight over 15 minutes, followed by an infusion at 0.2 to 0.7 mg/kg/h. Because of its longer half-life, dexmedetomidine was discontinued at bone closure (approximately 30 min before conclusion of surgery) so as not to delay the surgical schedule waiting for patients to awaken.
At induction, patients in both groups were given propofol (1 to 3 mg/kg), rocuronium (1 mg/kg), and fentanyl (1 to 3 mg/kg). Anesthesia was subsequently maintained with sevoflurane, adjusted to maintain an acceptable blood pressure (based on standard clinical protocol and the discretion of the anesthesiologist), which was discontinued when head pins were removed. Rocuronium was given to maintain 2 to 3 twitches. Fluids were given at the discretion of the anesthesiologist and inspired oxygen concentration varied depending on anesthesiologist preference. During closure of the bone flap or start of the closure in transsphenoidal procedures, fentanyl (50 mg) was administered to all the patients.
Postoperative analgesia was based on the verbal response score for pain with scores >4 usually prompting administration of 50 mg of fentanyl or equivalent, which was given as needed by nurses. Antiemetics were given when patients complained of nausea or vomited.
Measurements
The anesthesiologist was aware of the randomization but postoperative data were gathered by blinded investigators; the patients and surgeons were also blinded to randomization. Before surgery, each patient's baseline cognitive function was evaluated with the Short Orientation Memory Concentration Test (SOMCT), a validated questionnaire that discriminates among mild, moderate, and severe cognitive deficits. The 6 questions of the SOMCT yield a score ranging from 0 to 28, with higher scores indicating better function and scores >20 considered as normal. [21] [22] [23] In addition to routine anesthetic monitoring, a radial arterial catheter was inserted for continuous hemodynamic monitoring and blood sampling. Intraoperative blood pressure and heart rate, vasopressor use, and fluid administration were recorded in the electronic anesthesia record.
Upon emergence from anesthesia, time to eye opening, which was defined as the time when the patient first opened their eyes, or squeezed a hand, or wiggled their toes in response to verbal commands, was recorded. Lastly, the time that elapsed between extubation until patients could say their names in response to verbal prompting was evaluated.
Postoperative characteristics were recorded at 15, 30, 45, 60, and 90 minutes after postanesthesia care unit (PACU) admission, at which time data collection was concluded. Blood pressure and heart rate were determined from the arterial catheter. Pain was measured with a verbal response score (0 to 10), with zero indicating no pain. Fitness for PACU discharge was evaluated with a modified Aldrete score 24 ; patients transferred to ICU received a score of 0.
The nursing usage score, 25 based on the validated modified therapeutic index scoring system, 26 was completed 90 minutes after extubation. The maximum score possible is 22 with lower scores indicating fewer interventions and less time spent by nurses on the study patient. Opioids given during the initial 90 postoperative minutes were calculated and converted to morphine equivalents. 27 
STATISTICAL ANALYSIS
Sample size was based on being able to detect noninferiority on both analgesia (pain score and opioids) and hemodynamic responses, and superiority on at least one of them with 90% power and significance level of 0.025 for each of noninferiority and superiority. For verbal analogue score (VAS) pain, the SD was expected to be about 1.75, such that with a noninferiority delta of 1, we needed a maximum of N = 66 per group. For mean arterial pressure (MAP) with a noninferiority delta of 7.5 mm Hg and expected SD of 12, we needed a maximum of N = 65 per group. We assumed for opioids that the coefficient of variation (SD/mean) was about 0.4, resulting in a similar sample size (64/group) with noninferiority deltas of 20% of the observed mean. Similar power would be available to detect slightly larger differences for superiority testing. Incorporating the 2 interim and 1 final analyses, we thus planned a maximum sample size of N = 71/group (N = 142 total).
The primary outcomes were: (1) MAP at 15, 30, 45, 60, and 90 minutes after extubation; (2) pain scores measured at 15, 30, 45, 60, and 90 minutes after extubation; and (3) total opioid consumption during the initial 90 minutes of recovery. Secondary outcomes included postoperative heart rate, Aldrete recovery score, and modified short orientation memory concentration test score, nursing usage score at 90 minutes, side effects (nausea, vomiting, and shivering), and times to eye opening, name recall, fitness for discharge, and actual postanesthesia care unit discharge.
Two patients in the dexmedetomidine group who had missing pain scores at 15 and 30 minutes because of sedation were conservatively assigned the worst observed pain scores (10) . For 3 discrete missing blood pressure values, we used the last-observation carried-forward method. Balance on baseline characteristics and intraoperative factors between the 2 treatment groups were assessed using the standardized difference (STD, the difference in means or proportions divided by the pooled SD). Any factor with an absolute STDZ0.33 was considered imbalanced.
Primary Analyses
We used a joint hypothesis testing framework to assess whether dexmedetomidine was more effective than remifentanil, or vice versa, on hemodynamics and pain control. "More effective" was a priori defined as noninferior (ie, not worse) on both outcomes (hemodynamics and pain control) and superior on at least 1 of the 2 outcomes. Joint hypothesis testing was conducted as follows.
Pain Control
We tested noninferiority of dexmedetomidine to remifentanil on PACU opioid consumption using a 1-tailed Wilcoxon rank sum test, applying a noninferiority delta (a priori specified) equal to 20% of the median for the combined groups. Noninferiority on mean PACU pain score collapsed over time was assessed using a 1-tailed t test from a repeated measures analysis of variance (ANOVA) model, with prespecified noninferiority delta of 1 point on the VAS scale.
Hemodynamics
Noninferiority on MAP collapsed over time was similarly assessed using a 1-tailed t test from a repeated measures ANOVA model, with prespecified noninferiority delta of 7.5 mm Hg for MAP. Treatment effect estimates were summarized using difference in means between groups with interim-adjusted 95% confidence intervals (CIs). If noninferiority was found on all outcomes, superiority was tested in that same direction.
The overall significance level for noninferiority for each of pain control (PACU opioid consumption and pain score) and hemodynamics (MAP) was 0.05. With 2 directions for each outcome the significance criterion for a particular test within outcome was 0.05/2 = 0.025. No correction for testing both pain control and hemodynamics as primary outcomes was made as noninferiority was required on both pain control and hemodynamics to test superiority (ie, an intersection-union test). Similarly, no correction was made for including 2 variables to assess each of pain control and hemodynamics as both variables within each construct were required to be significant to claim noninferiority.
If noninferiority was shown for one of the interventions versus the other on both pain control and hemodynamics, 1-tailed superiority tests were conducted on each primary outcome with a significance criterion of 0.0125, or 0.025/2. Adjustment for multiple testing was made here as superiority of one drug over the other only required superiority on only 1 of the 2 constructs (pain control or hemodynamics).
Secondary Analyses
For repeat measures secondary outcomes (ie, heart rate, Aldrete score, and SOMCT score), linear-mixed effects model adjusting for baseline was used to assess the effect of treatments over time in tests for superiority. If no interaction (P < 0.10), we would assess the overall effect of treatments (collapsed over time); otherwise, we would assess the effect of treatments within 5 time points, and use Bonferroni correction (the criterion of significance P = 0.05/5 = 0.01).
We assessed the treatment effect on other continuous outcomes using 2-sided t or Wilcoxon sum rank tests, binary outcomes using w 2 test, and time-to-event outcome using Cox proportional hazard regression. All primary and secondary analyses were based on the modified intent-to-treat principle (patients withdrawn without receiving any of the study drug were excluded from all analyses). An as-treated analysis was performed on the primary analyses as a sensitivity analysis.
Interim-adjusted CI and Alpha Level
The utilized significance levels for each noninferiority and superiority test were 0.025 and 0.0125, respectively. In order to adjust for 2 interim analyses that followed a group sequential design with a gamma spending function and parameters of À 4 and À 2 for efficacy and futility, respectively, the results are reported with interim-adjusted CIs and alpha level, estimated using the Z-statistic efficacy criterion of 2.004, corresponding to an alpha of 0.0225, for the 1-tailed noninferiority test, and Z-statistic efficacy criterion of 2.25 (alpha of 0.01125) for the 1-tailed superiority tests. Furthermore, an interimadjusted alpha level of 0.045 was used for the 2-tailed tests for each secondary outcome to maintain the overall significant levels of 0.05. SAS 9.2 (Carey, NC) and East 5.3 (Cytel Inc.) were used for all analyses.
RESULTS
A total of 142 patients were randomized between July 2011 and March 2014. Three patients assigned to dexmedetomidine were withdrawn without receiving the study drug, and excluded from the study. Among the remaining 139 patients, 68 (49%) were assigned to dexmedetomidine and 71 (51%) to remifentanil; 1 patient assigned to remifentanil was given a lower dose of the study drug because of intraoperative hypotension (Fig. 1) .
Interim analyses at sample sizes of 48 and 96 were performed; no efficacy or futility boundaries were crossed. The analysis was performed on a "Group A" versus "Group B" basis with the results restricted to the Executive Committee that recommended continuing the trial after each analysis.
The demographic and morphometric characteristics were comparable between the 2 randomization groups. In addition, baseline and most intraoperative factors were balanced between the groups (ie, absolute standardized difference < 0.33), except that dexmedetomidine patients were given more intraoperative fentanyl and less labetalol. The duration of surgery was typically 3.5 to 4 hours ( Table 1) .
Primary Outcomes
Dexmedetomidine was significantly noninferior to remifentanil on both PACU morphine-equivalent opioid use and pain scores (Table 2) . Furthermore, superiority was found on both outcomes, with a median difference (97.5% CI) of À 5 (À 10, À 3; P < 0.001) mg for PACU morphine equivalents and a median difference of À 1.9 (À 2.8, À 0.9; P < 0.001) cm morphine equivalents. There was no significant group-by-time interaction on pain score (P = 0.11) (Fig. 2) .
Dexmedetomidine was found to be both noninferior and superior to remifentanil on mean PACU MAP (P < 0.001), with estimated difference in mean MAP (97.5% CI) of 10 (13, 4) mm Hg. Postoperative MAPs in patients given dexmedetomidine were similar to preoperative values. There was a significant group-by-time interaction on MAP with dexmedetomidine always being greater (P < 0.001) (Fig. 2) .
A sensitivity analysis based on treatment received (rather than randomization) showed similar results on both PACU pain management and hemodynamics. Few patients were given vasopressors (5/68 for dexmedetomidine and 0/71 for remifentanil) or antihypertensive medications (2 for dexmedetomidine and 4 for remifentanil) in the PACU (Appendix, Supplemental Digital Content 1, http://links.lww.com/JNA/A24); consequently, no statistical analysis was attempted.
Secondary Outcomes
Patients given dexmedetomidine had lower nursing resource usage scores than those randomized to remifentanil, with medians (quartiles) of 5.5 (5, 7) and P < 0.022). However, actual PACU discharge times were similar in each group. PACU heart rates were similar with dexmedetomidine and remifentanil. Aldrete scores, SOMCT scores, and side effects (nausea, vomiting, and shivering) were also similar. There was no treatment-bytime interaction for HR (P = 0.23), Aldrete scores (P = 0.98), or SOMCT scores (P = 0.12). No other adverse events deemed related to the study interventions were observed.
DISCUSSION
The primary result of this study is that craniotomy patients given intraoperative dexmedetomidine had significantly less pain and hypertension in the postanesthesia care unit compared to patients given remifentanil. Specifically, patients given dexmedetomidine required 5 mg less morphine equivalents and had pain scores that were lower by almost 2 points on a 0 to 10 verbal response scale.
Hypertension is especially a major concern in postcraniotomy patients. MAP in PACU was maintained around 88 mm Hg for dexmedetomidine versus 98 mm Hg for remifentanil. Although this difference is statistically significant, clinical intervention was not required. Although antihypertensive medications were rarely used in either group, a 10 mm Hg difference in MAP could be important in some patients, especially given the suggested association between hypertension and intracranial hemorrhage after craniotomy. 6 A previous study by Turgut et al 28 in 50 craniotomy patients maintained with propofol compared remifentanil with dexmedetomidine. Intraoperative MAPs were similar with each drug, which is consistent with our current results and previous work. 29 Intraoperative hemodynamic control was also similar in studies comparing dexmedetomidine to placebo in craniotomy 30 and dexmedetomidine to fentanyl in bariatric 31 patients.
Postoperative MAPs were also similar in each group studied by Turgut et al 28 at 20 minutes of recovery, but were slightly lower in the remifentanil patients at 120 minutes (85 vs. 92 mm Hg). Lower MAPs in the remifentanil patients may have resulted from their earlier requirement of supplemental analgesia (33 vs. 38 min). The results of Turgut et al 28 contrast with ours in that average PACU MAP over the initial 90 minutes was lower in the dexmedetomidine patients in our study. The difference could have been due to a lower number of patients enrolled in each group (25 remifentanil and 25 dexmedetomidine) compared with the current study, thus a difference may not have been observed. In addition, the differences in MAP observed by Turgut and colleagues were trivial.
Although the analgesic profile of dexmedetomidine has yet to be fully characterized in humans, the drug Data are presented as mean ± SD or median (quartiles), or treatment effect (CI, confidence interval).
P-values from 1-sided Wilcoxon rank sum tests for postanesthesia care unit (PACU) morphine equivalents and 1-tailed t test from repeated measures ANOVA model for pain score and MAP; Bonferroni correction was used for superiority testing since superiority on either hemodynamics or pain control would be interpreted as Dex better than Remi (a = 0.0125 = 0.025/2, 97.5% CI). No further adjustment within pain control outcomes as both required to be significant. *Significance level for noninferiority is 0.05 overall, and 0.025 in a given direction (eg, dexmedetomodine noninferior to remifentanil). Thus, noninferiority confidence intervals are 95% (a of 0.05/2 = 0.025 in direction of interest). wConfidence intervals are interim-adjusted and thus use critical Z-statistic of 2.004 (1-tailed) to maintain overall 0.025 significance level for both noninferiority and superiority testing. zAdjusted for baseline MAP in the repeated measures ANOVA. yUpper limit of 95% CI < delta indicates dexmedetomidine noninferior to remifentanil. Thus, noninferiority P-value significant (P < 0.0225, using interim-adjusted overall a of 0.045 and adjusting for testing in both directions). 8Superiority found on all outcomes as none of the 97.5% confidence intervals include zero. zDifference in medians with confidence interval was reported for noninferiority and superiority.
MAP indicates mean arterial pressure. Summary numbers for MAP and VAS pain score are collapsed over repeated measurements within a patient, and estimated from repeated measures ANOVA models. seems to have analgesic potential. [32] [33] [34] The mechanism of the analgesic action is thought to be at the dorsal horn of the spinal cord. 35 Consistent with this theory, patients reported less postoperative pain, and required significantly less opioid than those given remifentanil. We 36 and others have similarly reported postoperative analgesia after dexmedetomidine administration in craniotomy, 30, 37 transsphenoidal, 38 spinal, 39 and bariatric 31 patients. Differences in postoperative pain and opioid use may have been exaggerated by the use of remifentanil, a drug that has an extremely short duration of action and provokes hyperalgesia. 12, 40, 41 Dexmedetomidine has an onset-of-action of approximately 15 minutes after intravenous administration. Plasma concentrations typically stabilize after about an hour of constant drug infusion. It has a rapid distribution phase. Its steady state volume of distribution is 118 L, a distribution half-life (t ½ a) is 6 minutes in adults over the manufacturer-suggested dose ranges of 0.2 to 0.7 mg/kg/h, and an elimination half-life (t ½ b) of between 2.0 and 2.5 hours. 35 In contrast, remifentanil has a steady state volume of distribution of 30 L, 42 a context-sensitive half-life of about 3 minutes and an elimination half-life between 12 and 30 minutes. 43 We discontinued dexmedetomidine at bone closure, but continued remifentanil until the head was removed from the head-holder-a difference of 23 minutes. Nonetheless, because remifentanil is so short acting, its effect dissipated in our patients within a few minutes of discontinuation, whereas the effect of dexmedetomidine largely remained throughout our 90 minutes of postoperative evaluation. As might be expected, time to eye opening was noticeably longer in dexmedetomidine patients. Time to recall was also significantly longer in dexmedetomidine patients. Nonetheless, there were no statistically significant or clinically important differences in SOMCT cognition scores which is consistent with a previous report by Ohtani et al. 44 Nursing resource usage was lower in the dexmedetomidine patients, but probably not by a clinically important amount.
This study was limited by our inability to blind the anesthesiologist to the drug randomization because the dexmedetomidine arm had to stop drug administration earlier than the remifentanil arm (at bone closure vs. at removal of head from pins), which may introduce potential bias to the intraoperative anesthesia management. However, all intraoperative data were pulled from the electronic anesthesia record and all postoperative data collection was conducted by blinded coordinators. In addition, transsphenoidal surgeries tend to have less pain and markedly different operative and recovery characteristics than supratentorial and infratentorial craniotomy, but were included because they are intracranial procedures with the same anesthetic considerations. That being said, there were nearly equal numbers of transsphenoidal cases in both randomization arms.
In summary, intraoperative administration of dexmedetomidine provided better controlled postoperative MAP and superior analgesia compared with remifentanil in patients undergoing craniotomy for tumor excision. Cognitive recovery was similar in both groups, whereas eye opening and name recall were somewhat delayed in the dexmedetomidine group. Therefore, dexmedetomidine seems to be a reasonable alternative to remifentanil, and may be preferable in patients requiring tight hemodynamic control, particularly in the postoperative period.
